Loading…
Citius Oncology, Inc. is projected to decline to $0.6878 by 2027, a 0% move from its current price of $0.691. CTOR is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $0.6641 | $0.6909 | $0.7187 | -0.02% |
| Jul 14 | $0.6533 | $0.6908 | $0.7304 | -0.03% |
| Jul 15 | $0.645 | $0.6907 | $0.7396 | -0.05% |
| Jul 16 | $0.6381 | $0.6906 | $0.7473 | -0.06% |
| Jul 17 | $0.6321 | $0.6905 | $0.7542 | -0.08% |
| Jul 18 | $0.6267 | $0.6904 | $0.7604 | -0.09% |
| Jul 19 | $0.6218 | $0.6902 | $0.7662 | -0.11% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.6218 | $0.6902 | $0.7662 | -0.11% |
| Week 2 | $0.5948 | $0.6895 | $0.7993 | -0.22% |
| Week 3 | $0.5748 | $0.6887 | $0.8253 | -0.33% |
| Week 4 | $0.5583 | $0.688 | $0.8478 | -0.43% |
| Week 5 | $0.5441 | $0.6873 | $0.8681 | -0.54% |
| Week 6 | $0.5315 | $0.6865 | $0.8867 | -0.65% |
| Week 7 | $0.5202 | $0.6858 | $0.904 | -0.76% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
CTOR is a healthcare company focused on the development and commercialization of targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey, and operates as a subsidiary of Leonard-Meron Biosciences, Inc.
CTOR’s focus in oncology positions it within the healthcare sector, pursuing specialized therapies and orphan-condition treatment avenues for adults.
CTOR is currently trading at $0.7299 with a market capitalization of $67.87M. It ranks 4418 by market cap, placing it outside the top market leaders but within a defined niche in healthcare equities. The current price aligns with a projected near-term average of $0.7299 in 2026, indicating a flat near-term trajectory according to the forecast.
Looking ahead, the forecast foresees bullish momentum beginning in later years, with 2029 showing an average of $0.9933 and 2030 at $1.07, followed by continued upside through 2040 at $1.37 and into 2050 at $2.80. The projected price range expands toward a max of $6.16 by 2050, underscoring substantial long-term upside potential. The 2030 and 2050 outlooks carry bullish sentiment with ROI of 46.3% and 284.2%, respectively.
A major floor 28.7% below — a decisive break under it would weaken the trend.
The nearest floor, 10.3% below — buyers have tended to step in here.
The nearest ceiling, 16.8% above — a clean break opens room to run.
A major ceiling 57.7% above — clearing it would confirm fresh momentum.
Key CTOR support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CTOR market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.7122 | Sell | $0.7047 | Sell |
| MA 10 | $0.6906 | Buy | $0.6994 | Sell |
| MA 20 | $0.6837 | Buy | $0.7067 | Sell |
| MA 50 | $0.7867 | Sell | $0.7568 | Sell |
| MA 100 | $0.8217 | Sell | $0.8529 | Sell |
| MA 200 | $1.09 | Sell | $1.12 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 45.96 | Neutral |
| Stoch RSI (14) | 72.89 | Neutral |
| CCI (20) | 23.57 | Neutral |
| Williams %R (14) | -35.45 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | 0.88 | Buy |
| Bollinger %B (20,2) | 0.57 | Neutral |
| Stochastic %K (14) | 64.55 | Neutral |
| TRIX (15) | -0.60 | Sell |
| Awesome (5,34) | -0.02 | Sell |
| Ultimate (7,14,28) | 56.61 | Neutral |
| Momentum (10) | 0.03 | Buy |
| Aroon Osc (25) | -52.00 | Sell |
| Hull MA (9) | 0.72 | Sell |
| ADX (14) | 15.88 | Neutral |
| ATR (14) | 0.03 | Info |
The 30-day technical picture is NEUTRAL. RSI14 sits at 50, providing a balanced near-term momentum reading.
The 50-day simple moving average is $0.7933 and the 200-day simple moving average is $1.11, illustrating a potential headwind against a quickly rising longer-term trend. Support is at $0.62 and resistance at $0.889, framing a narrow near-term trading band. The 30-day trading range runs from $0.5568 to $0.9568, indicating there has been exposure to a broad intraday swing within the month.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.493 | $0.691 | $0.8133 | 0% | Neutral | |
| $0.525 | $0.6878 | $0.9658 | 0% | Neutral | |
| $0.5409 | $0.7393 | $1.09 | +7% | Neutral | |
| $0.6466 | $0.916 | $1.41 | +33% | Bullish | |
| $0.676 | $0.9885 | $1.57 | +43% | Bullish | |
| $0.5662 | $0.8526 | $1.39 | +23% | Bullish | |
| $0.5724 | $0.8861 | $1.48 | +28% | Bullish | |
| $0.5774 | $0.9174 | $1.57 | +33% | Bullish | |
| $0.5658 | $0.9219 | $1.61 | +33% | Bullish | |
| $0.7003 | $1.17 | $2.08 | +69% | Bullish | |
| $0.6741 | $1.26 | $2.43 | +82% | Bullish | |
| $1.15 | $2.55 | $5.49 | +269% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.493 | $0.691 | $0.8156 | +0.00% |
| August 2026 | $0.5503 | $0.6573 | $0.8117 | -4.88% |
| September 2026 | $0.5645 | $0.6813 | $0.8547 | +3.65% |
| October 2026 | $0.5647 | $0.6875 | $0.874 | +0.92% |
| November 2026 | $0.5269 | $0.6464 | $0.8309 | -5.98% |
| December 2026 | $0.5071 | $0.6264 | $0.8133 | -3.10% |
Click any year to see its month-by-month CTOR forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The CTOR price prediction for 2026 points to an average of $0.691 (low $0.493, high $0.8133) — a potential gain of 0% on today's $0.691. A consolidation phase looks the most probable path here.
In 2027, CTOR is projected to trade between $0.525 and $0.9658, averaging $0.6878 — a potential decline of 0% from today's $0.691. That is 0% versus the projected 2026 average. Price action looks broadly range-bound.
Citius Oncology, Inc.'s 2028 outlook centres on $0.7393, within a $0.5409 to $1.09 range. That is up +7% on the projected 2027 average. That marks a +7% change versus current levels. A consolidation phase looks the most probable path here.
By 2029, CTOR could reach as high as $1.41, with a base case around $0.916 and support toward $0.6466 — roughly +33% from $0.691. Momentum favours further upside here.
Expect CTOR to range from $0.676 to $1.57 through 2030. The $0.9885 average target implies a +43% move from current prices. That is up +8% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The CTOR price prediction for 2031 points to an average of $0.8526 (low $0.5662, high $1.39) — a potential gain of +23% on today's $0.691. Momentum favours further upside here.
In 2032, CTOR is projected to trade between $0.5724 and $1.48, averaging $0.8861 — a potential gain of +28% from today's $0.691. That is up +4% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Citius Oncology, Inc.'s 2033 outlook centres on $0.9174, within a $0.5774 to $1.57 range. That is up +4% on the projected 2032 average. That marks a +33% change versus current levels. Momentum favours further upside here.
By 2034, CTOR could reach as high as $1.61, with a base case around $0.9219 and support toward $0.5658 — roughly +33% from $0.691. Buyers look set to stay in control over this stretch.
Expect CTOR to range from $0.7003 to $2.08 through 2035. The $1.17 average target implies a +69% move from current prices. That is up +27% on the projected 2034 average. Momentum favours further upside here.
The CTOR price prediction for 2040 points to an average of $1.26 (low $0.6741, high $2.43) — a potential gain of +82% on today's $0.691. Buyers look set to stay in control over this stretch.
In 2050, CTOR is projected to trade between $1.15 and $5.49, averaging $2.55 — a potential gain of +269% from today's $0.691. That is up +102% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in CTOR today (≈ 1,447.178003 CTOR) could be worth
$3,689.06
+$2,689.06 (+269%) by 2050 · US Dollar
Based on the average projected CTOR price of $2.55 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CTORwould be worth at today's price.
$1,000 invested in CTOR on Jul 10, 2025 (≈ 307.692308 CTOR) would be worth
$212.62
-$787.38 (-78.7%) today · 0.21× · US Dollar
Based on a CTOR entry price of $3.25 vs. today's $0.691.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.68 | $1,016.18 | +1.6% |
| 1 month ago | $0.687 | $1,005.82 | +0.6% |
| 3 months ago | $0.675 | $1,023.7 | +2.4% |
| 6 months ago | $1.07 | $645.79 | -35.4% |
| 1 year ago | $3.25 | $212.62 | -78.7% |
| All time (3.6y) ago | $10.09 | $68.48 | -93.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CTOR forecast.
Our base-case forecast reaches $1.40 around 2050.
Implied market cap at $1.40: $130.17M
The multi-year forecast shows a path of gradual appreciation with notable accelerations later in the period. The 2029 average is $0.9933, the 2030 average is $1.07, and the 2040 average is $1.37, with corresponding max values of $1.54, $1.71, and $2.68 respectively. The 2035 forecast gives an average of $1.29 and a max of $2.32, signaling continued bullish momentum ahead of 2040.
By 2050, the forecast projects an average of $2.80 and a max of $6.16, with a strong bullish sentiment reflected in the numbers.
In terms of ROI, the forecast shows 0% in 2026, 0.5% in 2027, 9.1% in 2028, 36.1% in 2029, 46.3% in 2030, 24.8% in 2031, 31.3% in 2032, 36% in 2033, 36.6% in 2034, 76.5% in 2035, 87.8% in 2040, and 284.2% in 2050. The sentiment remains BULLISH from 2029 onward, reflecting a positive longer-term outlook while acknowledging that these are estimates, not guarantees. The forecast is shown with an annualized volatility backdrop of 80%, highlighting the high-risk, high-reward nature of the equity.
Tap a question to reveal the answer.
The forecast for 2030 shows an average price of $1.07 with a min of $0.722 and a max of $1.71, and a projected ROI of 46.3% with a BULLISH sentiment.
Forecasts show bullish sentiment from 2029 onward, with 2030 average at $1.07, 2040 at $1.37, and 2050 at $2.80 accompanied by a 284.2% ROI. These are estimates and not guarantees.
Yes. The 2035 max is $2.32 and the 2040 max is $2.68, with a 2050 max of $6.16, indicating potential for prices above $2 in mid-to-late horizon.
The 2029 forecast shows an average price of $0.9933 with a min of $0.6945 and a max of $1.54, and a ROI of 36.1% with a BULLISH sentiment.
The 30-day picture shows NEUTRAL sentiment, RSI 50, SMA50 at $0.7933, SMA200 at $1.11, support at $0.62, resistance at $0.889, and a 30-day range from $0.5568 to $0.9568.
Citius Oncology, Inc. Community Discussion
0Share your Citius Oncology, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.